Short Interest in Protalix BioTherapeutics Inc. (PLX) Decreases By 5.4%

Protalix BioTherapeutics Inc. (NYSE:PLX) was the target of a significant decrease in short interest in September. As of September 15th, there was short interest totalling 712,565 shares, a decrease of 5.4% from the August 31st total of 753,510 shares. Based on an average trading volume of 134,386 shares, the days-to-cover ratio is currently 5.3 days. Currently, 0.8% of the company’s stock are short sold.

Several brokerages recently issued reports on PLX. Zacks Investment Research lowered shares of Protalix BioTherapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, August 24th. Rodman & Renshaw reissued a “buy” rating on shares of Protalix BioTherapeutics in a research note on Monday, July 11th. Finally, Jefferies Group cut their target price on shares of Protalix BioTherapeutics from $1.75 to $0.80 and set a “buy” rating on the stock in a research note on Tuesday, September 6th.

Protalix BioTherapeutics (NYSE:PLX) opened at 0.5699 on Tuesday. The company has a market capitalization of $56.85 million and a price-to-earnings ratio of 1.1263. Protalix BioTherapeutics has a 1-year low of $0.56 and a 1-year high of $1.33. The firm has a 50 day moving average of $0.61 and a 200-day moving average of $0.73.

Protalix BioTherapeutics (NYSE:PLX) last posted its quarterly earnings results on Monday, August 8th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.08) by $0.03. The business had revenue of $1.77 million for the quarter, compared to analysts’ expectations of $1.34 million. During the same quarter in the previous year, the business earned ($0.05) earnings per share. On average, equities research analysts anticipate that Protalix BioTherapeutics will post ($0.41) earnings per share for the current fiscal year.

5 Day Chart for NYSE:PLX

Receive News & Ratings for Protalix BioTherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix BioTherapeutics Inc. and related companies with's FREE daily email newsletter.

Leave a Reply

© 2006-2016 Mideast Time.